A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Save

Date Added
July 21st, 2016
PRO Number
Pro00037394
Researcher
Caio Rocha lima
Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as selinexor, gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

Change_preferences

-- OR --

Create_login